XRTX to Consolidate Shares 1-for-5 Effective April 6 After Exchange Approvals
XRTX Therapeutics will implement a one-for-five share consolidation effective April 6, 2026, after TSXV and Nasdaq approvals. The reduction in issued common shares realigns capital ahead of key clinical milestones in gout and kidney disease programs.
1. Share Consolidation Details
XRTX Therapeutics will exchange every five existing common shares for one new common share, reducing the total outstanding share count by 80%. This corporate action is designed to tighten the capital structure and potentially enhance per-share metrics.
2. Approval and Effective Date
The share consolidation received all required approvals from the TSX Venture Exchange and Nasdaq Stock Market. The process is scheduled to occur on April 6, 2026, with trading to resume on a consolidated basis following the effective date.
3. Company Overview
XRTX Therapeutics is a late-stage clinical pharmaceutical company developing therapies for gout, autosomal dominant polycystic kidney disease and acute organ injury. Its lead programs target aberrant purine metabolism and xanthine oxidase to reduce uric acid production.